reportingrisk.com← the monitorSEC reporting failures, scored and checked against what happened next

Or browse all companies A–Z.

Astrana Health, Inc.

ASTH · Nasdaq

1 reporting failure in the last 12 months

Companies at this level ended the following year delisted, bankrupt, restated or silent 9.2% of the time, against 4.0% for companies with a clean record.

$1.1Bpublic float
2026-03-02most recent failure
2023-08-07declared past accounts unreliable

Score over time

012202220232024202520262023-10-01 · score 12023-08-07 accounts unreliable2024-01-01 · score 12023-08-07 accounts unreliable2024-04-01 · score 12023-08-07 accounts unreliable2024-07-01 · score 12023-08-07 accounts unreliable2025-04-01 · score 12025-02-27 filed late (10-K) · investigation2025-07-01 · score 12025-02-27 filed late (10-K) · investigation2025-10-01 · score 12025-02-27 filed late (10-K) · investigation2026-01-01 · score 12025-02-27 filed late (10-K) · investigation2026-04-01 · score 12026-03-02 filed late (10-K) · material weakness2026-07-01 · score 12026-03-02 filed late (10-K) · material weakness2026-10-01 · score 12026-03-02 filed late (10-K) · material weakness

Hover or tap a dot to see the filings behind that score.

Why they said they were late

Astrana Health, Inc. (the “Company”) is unable to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (the “2025 Form 10-K”) within the prescribed time period without unreasonable effort or expense. The 2025 Form 10-K cannot be filed by the prescribed due date because additional time, resources and effort are required to complete work related to the Company’s financial reporting and close procedures, specifically as a result of the Company’s acquisition of certain entities. In connection with the filing of the 2025 Form 10-K, when made, the Company anticipates reporting a material weakness in the Company’s internal control over financial reporting, which is expected to relate to, but may not be limited to, the Company’s acquisition and purchase accounting processes. As a result of the expected material weakness, the Company believes that its internal control over financial reporting was not effective, and its disclosure controls and procedures were not effective, as of December 31, 2025. The Company is developing a remediation plan that will be described further in the 2025 Form 10-K. The Company currently expects to file the 2025 Form 10-K within the fifteen-day extension period provided under Rule 12b-25 of the Securities Exchange Act of 1934, as amended. Although the 2025 Form 10-K is not completed, the Company expects that the financial statements in the 2025 Form 10-K will be substantially consistent with the financial information reported in the earnings release for the quarter and year ended December 31, 2025

NT 10-K, filed 2026-03-02 · material weakness

What it filed

2026-03-02filed late (10-K)material weakness SEC →

Astrana Health, Inc. (the “Company”) is unable to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (the “2025 Form 10-K”) within the prescribed time period without unreasonable effort or expense. The 2025 Form 10-K cannot be filed by the prescribed due date because additional time, resources and effort are required to complete work related to the Company’s financial reporting and close procedures, specifically as a result of the Company’s acquisition of certain entities. In connection with the filing of the 2025 Form 10-K, when made, the Company anticipates reporting a material weakness in the Company’s internal control over financial reporting, which is expected to relate to, but may not be limited to, the Company’s acquisition and purchase accounting processes. As a result of the expected material weakness, the Company believes that its internal control over financial reporting was not effective, and its disclosure controls and procedures were not effective, as of December 31, 2025. The Company is developing a remediation plan that will be described further in the 2025 Form 10-K. The Company currently expects to file the 2025 Form 10-K within the fifteen-day extension period provided under Rule 12b-25 of the Securities Exchange Act of 1934, as amended. Although the 2025 Form 10-K is not completed, the Company expects that the financial statements in the 2025 Form 10-K will be substantially consistent with the financial information reported in the earnings release for the quarter and year ended December 31, 2025

2025-02-27filed late (10-K)investigation SEC →

Astrana Health, Inc. (the “Company”) is unable to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the “2024 Form 10-K”) within the prescribed time period without unreasonable effort or expense. The 2024 Form 10-K cannot be filed by the prescribed due date because additional time, resources and effort are required to complete work related to the Company’s financial reporting and close procedures, specifically as it relates to the Company’s acquisition of certain entities in the fourth quarter of 2024. The Company currently expects to file the 2024 Form 10-K within the fifteen-day extension period provided under Rule 12b-25 of the Securities Exchange Act of 1934, as amended. Although the 2024 Form 10-K is not completed, the Company expects that the financial statements in the 2024 Form 10-K will be substantially consistent with the financial information reported in the earnings release for the three and twelve months ended December 31, 2024. Forward-Looking Statements This Form 12b-25 contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties, including statements regarding the Company’s expectations regarding the timing of filing its 2024 Form 10-K on or before the fifteenth day following its prescribed due date (the “extension deadline”), the consistency of the financial statements in the 2024 Form 10-K with the financial information in the earnings release and the completion of matters necessary to permit filing by the extension deadline. Such forward-looking statements are based on assumptions about many important factors that could cause actual results to differ materially from those in the forward-looking statements, including risks identified in the Company’s most recent filing on Form 10-K and other SEC filings, all of which are available on the Company’s website

2023-08-07accounts declared unreliable SEC →

About this score

reportingrisk.com scores every active US filer on three things a company tells the SEC about itself: late-filing notices on Form NT, 8-K item 4.02 (past accounts declared unreliable) and 4.01 (auditor changes). 1,012 are flagged today.

Every score is frozen and checked twelve months later. Across 91,452 of them, a company scoring 4 or more ended that year delisted, bankrupt, restated or silent 17.2% of the time, against 4.0% for a clean record. Scores before 2026-09-27 were reconstructed from the filing history as it stood at each date, so the record is a backtest rather than years of live calls.

See the ledger → Every company the score flagged that later failed, what it told the SEC on the way down, and the ones it missed.

Every item above is a filing this company made with the SEC.
Snapshot 2026-11-04 · data from SEC EDGAR (public domain) · not investment advice

reportingrisk.com← back to the monitorAll companies A-Z · RSS · found an error? hello@reportingrisk.com